Skip to content
Calculator
Guide

SS-31 became a drug: what elamipretide's approval means and doesn't

Last updated: October 27, 2026 · 4 min read · By the Grey Peptides Editorial Board

Pharmacist with turban organizing shelves in a pharmacy, focused on healthcare
Photo by World Sikh Organization of Canada on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • SS-31 is now an FDA-approved drug: elamipretide, sold as Forzinity, received accelerated approval on September 19, 2025 to improve muscle strength in people with Barth syndrome, a rare inherited mitochondrial disease, who weigh at least 30 kg.
  • The approval is narrow and conditional. It rests on a muscle-strength measure in a handful of patients, after a randomised trial that missed its main goals; continued approval may depend on a confirmatory trial.
  • It does not validate other uses. The large trials of SS-31 in mitochondrial myopathy, heart failure and dry macular degeneration missed their main goals, and gray-market vials are not the approved product.

What was approved

Elamipretide High, long known in research as SS-31, binds cardiolipin, a lipid of the inner mitochondrial membrane; the foundational studies showed this binding in mitochondria 1. On September 19, 2025 the FDA approved it under priority review as Forzinity, from Stealth BioTherapeutics 2. The label's indication is precise: to improve muscle strength in adult and paediatric patients with Barth syndrome who weigh at least 30 kg 3. The dose is 40 mg injected under the skin once a day, reduced in adults with severe kidney impairment 3. The label's warnings are benzyl-alcohol toxicity in newborns, from an ingredient of the formulation, and hypersensitivity reactions 3.

A 2025 review calls it the first disease-specific treatment approved for Barth syndrome, an ultra-rare X-linked genetic disorder 4. As of October 27, 2026, Drugs@FDA lists it as a prescription product 2.

Why "accelerated" matters

FDA describes accelerated approval as a route to earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on an end point thought to predict clinical benefit that is not itself a measure of it; companies must still run studies to confirm the benefit 5. Forzinity's label says its approval was based on an improvement in knee-extensor muscle strength, an intermediate clinical end point, and that continued approval may depend on a confirmatory trial verifying clinical benefit 3.

The evidence behind it is small. TAZPOWER randomised 12 people with Barth syndrome to 12 weeks of elamipretide 40 mg a day or placebo, then a washout and 12 weeks on the other arm; neither primary end point, six-minute walk or a symptom scale, was met 6. In the open-label extension that followed, knee extensor strength was among the secondary measures that improved by week 36 6; 10 patients continued on 40 mg daily and 8 reached 168 weeks, with a cumulative 96.1-metre gain in six-minute walk distance and fatigue scores below baseline 7. A comparison of 8 treated patients with 19 untreated patients from a natural-history study found a 79.7-metre advantage in six-minute walk distance at week 64 8. Open-label results and comparisons with untreated patients cannot rule out the biases a randomised comparison removes.

Where SS-31 did not work

The same molecule has been tested in larger populations, and the results are the reason the approval should not be read broadly. In MMPOWER-3, a phase 3 trial, 218 adults with genetically confirmed primary mitochondrial myopathy received 40 mg daily or placebo for 24 weeks; it did not improve the six-minute walk test or fatigue scores 9. In PROGRESS-HF, 71 people with heart failure and reduced ejection fraction received 4 or 40 mg daily or placebo for 28 days; the primary heart-imaging end point did not differ between groups 10. In ReCLAIM-2, a 48-week trial in dry age-related macular degeneration, the primary vision and lesion-size end points were not met, although exploratory measures of photoreceptor integrity favoured the drug, and injection-site reactions were the most common reason for stopping treatment early on elamipretide (17.1%) 11.

Development has not stopped: a review written after approval reports elamipretide in phase 3 development for dry age-related macular degeneration and mitochondrial myopathies 4. Until those trials report, the only use the evidence and the label support is the one approved.

What the approval does not mean

The approval does not support SS-31 for energy, ageing, endurance or recovery. It covers one formulation, one dose and one rare disease, on the strength of a muscle-strength measure; the trials in common conditions that people might hope to treat missed their main goals 9 10 11. A vial labelled SS-31 from a research-chemical site is also not Forzinity: only the approved product's manufacture and labelling were reviewed by FDA 2 3.

For sport, SS-31 is not named on WADA's 2026 or 2027 Prohibited List, and as an approved drug it is not caught by S0, according to our entry's review of the List 12. That is a statement about doping rules, not about safety or benefit.

Frequently asked questions

Is SS-31 FDA-approved?

Yes, as elamipretide (Forzinity), under accelerated approval on September 19, 2025, to improve muscle strength in people with Barth syndrome weighing at least 30 kg. That is its only approved use.

Does the approval mean SS-31 works for anti-ageing or energy?

No. It covers one rare disease. Trials in primary mitochondrial myopathy, heart failure and dry macular degeneration missed their primary end points.

What is the approved dose of elamipretide?

40 mg injected under the skin once daily for patients weighing at least 30 kg, reduced in adults with severe kidney impairment, according to the Forzinity label.

Is research-grade SS-31 the same as Forzinity?

No. Products sold as research chemicals are not the approved drug, and FDA's review covered only Forzinity.

Sources

  1. Birk, A. V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol, 24(8), 1250-61. PMID: 23813215
  2. US FDA, Drugs@FDA (openFDA): FORZINITY, NDA 215244, original approval September 19, 2025, priority review; prescription. Read October 2, 2026; status re-checked October 27, 2026.
  3. Stealth BioTherapeutics. FORZINITY (elamipretide hydrochloride) injection US prescribing information (DailyMed set 146bf34c-76f2-48db-ac07-fb29cce2cd75, version 10, effective December 10, 2025; confirmed current on DailyMed October 27, 2026). DailyMed
  4. Shirley, M. (2026). Elamipretide: First Approval. Drugs, 86(3), 377-383. PMID: 41335372
  5. US Food and Drug Administration. Accelerated Approval Program (content current as of August 25, 2026); read October 27, 2026. FDA
  6. Reid Thompson, W., et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med, 23(3), 471-478. PMID: 33077895
  7. Thompson, W. R., et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med, 26(7), 101138. PMID: 38602181
  8. Hornby, B., et al. (2022). Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis, 17(1), 336. PMID: 36056411
  9. Karaa, A., et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology, 101(3), e238-e252. PMID: 37268435
  10. Butler, J., et al. (2020). Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail, 26(5), 429-437. PMID: 32068002
  11. Ehlers, J. P., et al. (2025). ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmol Sci, 5(1), 100628. PMID: 39605874
  12. Grey Peptides dataset, ss-31 record (WADA 2026 and 2027 review); read October 27, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead